DALACIN T LOTION 1% Singapore - English - HSA (Health Sciences Authority)

dalacin t lotion 1%

pfizer private limited - clindamycin phosphate eqv clindamycin - lotion - 1.00% - clindamycin phosphate eqv clindamycin 1%

Dalacin T 1% topical lotion United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalacin t 1% topical lotion

pfizer ltd - clindamycin phosphate - cutaneous emulsion - 10mg/1ml

DALACIN VAGINAL OVULES Israel - English - Ministry of Health

dalacin vaginal ovules

pfizer pfe pharmaceuticals israel ltd - clindamycin as phosphate - ovules - clindamycin as phosphate 100 mg - clindamycin - clindamycin - dalacin vaginal ovules are indicated for 3-day treatment of bacterial vaginosis .

Dalacin T 1% topical lotion United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalacin t 1% topical lotion

lexon (uk) ltd - clindamycin phosphate - cutaneous emulsion - 10mg/1ml

Dalacin T 1% topical lotion United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalacin t 1% topical lotion

waymade healthcare plc - clindamycin phosphate - cutaneous emulsion - 10mg/1ml

Dalacin T 1% topical lotion United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalacin t 1% topical lotion

sigma pharmaceuticals plc - clindamycin phosphate - cutaneous emulsion - 10mg/1ml

DALACIN V clindamycin 2% (20mg/g) (as phosphate) cream tube Australia - English - Department of Health (Therapeutic Goods Administration)

dalacin v clindamycin 2% (20mg/g) (as phosphate) cream tube

pfizer australia pty ltd - clindamycin phosphate, quantity: 22.8 mg/g (equivalent: clindamycin, qty 20 mg/g) - cream - excipient ingredients: purified water; polysorbate 60; benzyl alcohol; stearic acid; cetyl esters wax; propylene glycol; liquid paraffin; sorbitan monostearate; cetostearyl alcohol - dalacin v cream 2% is indicated for the treatment of symptomatic bacterial vaginosis. note: for the purposes of this indication bacterial vaginosis is usually defined by positive results to at least three of the four following criteria: 1. vaginal discharge with ph > 4.5; 2. vaginal discharge demonstrating an amine ("fishy") odour with the addition of 10% potassium hydroxide; 3. vaginal discharge with "clue cells" on microscopy, and; 4. a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent or markedly decreased; gardnerella morphotype predominant flora; white blood cells absent or few; mobiluncus morphotype may or may not be present). other pathogens which may be associated with genital infection such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae should be ruled out by appropriate laboratory means.

Dalacin T 1% topical lotion United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalacin t 1% topical lotion

mawdsley-brooks & company ltd - clindamycin phosphate - cutaneous emulsion - 10mg/1ml

DALACIN C clindamycin 600 mg/4 mL (as phosphate) injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dalacin c clindamycin 600 mg/4 ml (as phosphate) injection ampoule

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: water for injections; benzyl alcohol; sodium hydroxide; disodium edetate; hydrochloric acid - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate gram

DALACIN C clindamycin 300mg/2mL (as phosphate) injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dalacin c clindamycin 300mg/2ml (as phosphate) injection ampoule

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: disodium edetate; hydrochloric acid; water for injections; sodium hydroxide; benzyl alcohol - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract) and infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate g